Cumberland Is Selling the Core Business for More Than Its Market Cap

TLDR

Cumberland Pharmaceuticals, CPIX -3.62%↓ , has an ~$88M market cap, no long-term debt, and a signed agreement to sell its commercial assets for $100M in upfront cash — while retaining its ifetroban pipeline.

Overview

The setup looks unusually clean for a microcap pharma special situation. It’s too small for mid-sized funds to buy so it’s being overlooked.

Read the rest of this article

The rest of this piece is free.

No account and no payment. We send the work, not marketing.

Still to come

Transaction History
Deal Structure
Next Steps (as of May 27th)
What happens to Cumberland after the acquisition?
Quick side note
Conclusion

Recommended

Research
AAOI vs. COHR: How Much Upside Is Left?
August 18, 2026
Research
AI Is a Bubble Only If You Refuse to Define AI
June 4, 2026
Research
Michael Burry is wrong about AI and Nvidia
June 1, 2026
Research
If You Think AI Demand Is Booming, Wait Until Your Girlfriend Starts Sending Outfit Pics
May 27, 2026

Filed under

CPIXSpecial SituationsBiotechValuationPharmaceutical Preparations

For informational purposes only — not investment advice.